Genetic analysis of tumors of patients with ACC showed that a significant number of tumors had mutations involving the FGF-PI3K-AKT pathway [33], however the AKT-inhibitor MK-2206 and the mTOR inhibitor everolimus showed no responses in ACC patients [34, 35]. Here, MTOR is linked to adrenal cortex carcinoma.